Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the possibility and safety of adding minoxidil sulfate to mesotherapy with dutasteride. Users are inquiring if anyone has tried this combination.

Exosomes, cetirizine, melatonin, latanoprost, and caffeine are discussed as potential hair loss treatments. There is skepticism about the effectiveness of exosomes, especially in topical form, but some users report positive results.

Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.

A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

The conversation discusses concerns about MVSupplements.com products, specifically the Min+Ru spray and GHK Serum, due to discrepancies in ingredient lists and recent poor feedback. Users also mention a price increase and one user reports no issues with the RU powder.

Increasing the sult1a1 enzyme on the scalp may improve response to topical minoxidil. The user suggests using a baking soda solution, DMSO, and tretinoin to enhance enzyme activity and minoxidil effectiveness.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.

The conversation discusses concerns about Dr. Rassman's topical Finasteride, specifically whether it is liposomal or glycol-based. Dr. Rassman insists on providing the correct liposomal formulation and urges patients to contact him if they receive the wrong product.

A user suspects Ritalin is causing hair loss due to vasoconstriction and is considering trying Ginkgo Biloba after already taking a multivitamin and hair supplement. Another user mentions experiencing hair shedding with Vyvanse and Dexedrine.

OP wants to buy fluridil from China and needs advice on mixing it in a topical solution due to budget constraints. They cannot afford Eucapil.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.

A sugar gel was claimed to trigger hair regrowth, but users reported no results and potential cancer risks. The discussion included comparisons to minoxidil and skepticism about the effectiveness of the sugar treatment.

Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.

The solution contains minoxidil, finasteride, azelaic acid, caffeine, retinoic acid, and procapil. Users suggest minoxidil with tretinoin and a 5-alpha reductase inhibitor, while dismissing retinoic and azelaic acids as unnecessary.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

Dutasteride is more effective in gel capsule form due to better absorption, as it is fat-soluble. If only pills are available, taking them with fat or increasing the dose slightly may help.

User discusses a topical hair solution containing Tretinoin, Dutasteride, and Ketoconazole, and asks if it's safe to combine and leave in hair. Concerns include Ketoconazole being left in hair and Tretinoin's effects with Dutasteride and Ketoconazole.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

Topical Vitamin D3 may stimulate hair growth and has been used for Alopecia Areata. There is a question about the lack of research on its use for Androgenetic Alopecia (AGA).

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.